Online citations, reference lists, and bibliographies.
← Back to Search

Impact Of Switching From Human Immunodeficiency Virus Type 1 Protease Inhibitors To Efavirenz In Successfully Treated Adults With Lipodystrophy.

E. Martinez, M. García-Viejo, J. Blanco, L. Bianchi, E. Buira, I. Conget, R. Casamitjana, J. Mallolas, J. Gatell
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
We prospectively followed 20 consecutive patients with human immunodeficiency virus type 1 (HIV-1) with viral loads of <200 RNA copies/mL. These patients had been treated with 2 nucleoside reverse transcriptase inhibitors and > or =1 HIV-1 protease inhibitor for > or =3 months; they developed body changes consistent with lipodystrophy and requested they be switched from protease inhibitor to efavirenz. At baseline and every 3 months, we assessed the following: body mass index, waist-to-hip ratio, regional fat thickness (assessed by sonography), fasting total and high-density lipoprotein cholesterol, triglycerides, glucose, insulin, CD4(+) cells, and viral load. At baseline, hypertriglyceridemia (> or =200 mg/dL) was present in 17 (85%) patients, hypercholesterolemia (> or =200 mg/dL) in 14 (70%), and impaired fasting glucose (> or =110 mg/dL) in 8 (40%); CD4(+) T cells were 280x10(6) cells/L (range, 64-942x10(6) cells/L). HIV-1 RNA had been at <200 copies/mL for a median of 14 months (range, 3-24 months). Six months after switching to efavirenz, there was a reduction in triglyceride levels (a decrease of 31%; P=.03) and fasting insulin resistance index (a decrease of 28%; P=.03), but total and high-density lipoprotein cholesterol and glucose did not change. Waist-to-hip ratio decreased from 0.92 to 0.87 (P=.06). Subcutaneous fat thickness did not change. CD4(+) cells remained stable (363x10(6) cells/L; range, 102-741x10(6) cells/L; P=.65). Nineteen patients (95%) had HIV-1 RNA levels that remained at <200 copies/mL. Although CD4(+) response and viral suppression remained preserved after 6 months of switching from protease inhibitor to efavirenz, the benefits of this approach on the evolution of lipodystrophy were limited, and our findings do not support its routine recommendation to treat lipodystrophy.
This paper references
Sonography detection of small intra-abdominal fat variations.
F. Armellini (1991)
10.1093/CLINIDS/17.4.802
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
K. Castro (1992)
10.1001/JAMA.1994.03520030047027
Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991.
R. Kuczmarski (1994)
10.1016/0163-7827(94)00006-8
Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity.
N. Abate (1995)
10.1016/S0140-6736(95)92143-5
A simple measure of insulin resistance
M. Duncan (1995)
10.1097/00042560-199702010-00013
Detection of low HIV-1 RNA levels in plasma.
G. A. Schockmel (1997)
10.1016/S0140-6736(97)11518-5
Visceral abdominal-fat accumulation associated with use of indinavir
K. Miller (1998)
10.1097/00002030-199806000-00001
HIV risk behavioral surveillance: a methodology for monitoring behavioral trends.
S. Mills (1998)
10.1097/00002030-199806000-00001
Indinavir‐associated lipodystrophy
R. Viraben (1998)
10.1016/S0140-6736(97)11443-X
“Buffalo hump” in men with HIV-1 infection
J. Lo (1998)
10.1016/S0889-8529(05)70028-1
Detection and evaluation of dyslipoproteinemia.
J. Cleeman (1998)
10.1038/sj.ijo.0800660
Selection of anthropometric indicators for classification of abdominal fatness— a critical review
A. Molarius (1998)
10.1097/00002030-199807000-00003
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
A. Carr (1998)
Cumulative risk for developing protease inhibitor-associated lipodystrophy [abstract I-92
A Veny (1998)
Indinavir-associated lipodystrophy. AIDS 1998;12: F37–9
R Viraben (1998)
10.1097/00002030-199904160-00020
Lipodystrophy in patients naive to HIV protease inhibitors.
S. Madge (1999)
10.1097/00002030-199905070-00009
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
E. Martinez (1999)
10.1016/S0140-6736(98)08468-2
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
A. Carr (1999)
10.1093/AJCN/69.6.1162
Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging.
E. Engelson (1999)
10.1097/00002030-199905280-00023
Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.
T. Saint-Marc (1999)
10.1097/00002030-199907300-00015
A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution.
R. Roubenoff (1999)
10.1056/NEJM199912163412501
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
S. Staszewski (1999)
10.1097/00002030-199910220-00035
The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy.
T. Saint-Marc (1999)
10.1097/00002030-199910220-00013
Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV.
C. Wanke (1999)
10.1097/00002030-199911120-00008
Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy.
P. Domingo (1999)
10.1097/00002030-199909100-00009
A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
T. Saint-Marc (1999)
Management of protease inhibitor–associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons [abstract 2064
GJ Moyle (1999)
Potential adverse experiences associated with efavirenz in adults [abstract 655
NM Ruiz (1999)
Switch to AZT plus 3TC improves lipodystrophy in the presence of protease inhibitors [abstract 1306
R Polo (1999)
Lack of clinical lipodystrophy in patients receiving efavirenz plus NRTIs in Study 006 [abstract 1304
K Tashima (1999)
Reversibility of protease inhibitor lipodystrophy syndrome on stopping protease inhibitors or switching to nelfinavir [ abstract 668 ]
A Carr (1999)
Efavirenz as a substitute for protease inhibitors in HIV-infected patients on triple-drug therapy with plasma viral load below 20 copies/mL [abstract 2196
D Rey (1999)
Replacing a protease inhibitor with efavirenz for management of protease inhibitor toxicity [abstract 051
M Harris (1999)
Prospective follow - up of a protease inhibitor substitution for efavirenz in patients with HIV - related lipodystrophy syndrome [ abstract 068 ]
W Rozembaum (1999)



This paper is referenced by
10.14233/ajchem.2020.22440
Design, Synthesis, Molecular Docking and Antimicrobial Evaluation of Some Tosyl Carbamate Derivatives
P. Kalaivani (2020)
10.1093/femsre/fuaa008
Molecular Determinants of Surface Colonisation in Diarrhoeagenic Escherichia coli (DEC): from Bacterial Adhesion to Biofilm Formation.
Valentin Ageorges (2020)
10.2337/ds17-0009
Prevalence of and Risk Factors for Prediabetes in Patients Infected With HIV
S. Arafath (2018)
10.1016/S2055-6640(20)30335-6
Serum lipid and glucose profiles in HIV-positive Nigerian children
O. Ige (2017)
10.1007/978-3-319-20797-1_38-1
HIV Infection and Diabetes
Swaytha Yalamanchi (2016)
10.1002/dmrr.2792
Prediabetes and diabetes among HIV‐infected adults in Cameroon
J. Y. Rhee (2016)
Syndrome de lipodystrophie associé au VIH : examen des aspects cliniques
Jean-Guy Baril (2016)
10.1136/bcr-2014-208053
The successful use of lipectomy in the management of airway obstruction in a woman with HIV-associated lipodystrophy
Edison W Tsui (2015)
10.1039/c4cc00538d
PdCl2 catalyzed efficient assembly of organic azides, CO, and alcohols under mild conditions: a direct approach to synthesize carbamates.
L. Ren (2014)
10.1371/journal.pone.0061160
Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial
M. Glesby (2013)
Pharmacotherapy of human immunodeficiency virus infection
J. Adams (2013)
10.1007/s11154-013-9245-9
Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS
S. Jain (2013)
10.1007/s00431-013-2018-3
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz
V. Fabiano (2013)
10.1590/S1677-54492012000200009
Antirretroviral therapy effect in the intima-medio complex and ankle-brachial index in patients infected by HIV
E. T. Godoi (2012)
10.1093/jac/dkr558
Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors.
Pei‐Ying Wu (2012)
10.4172/2155-6113.1000143
HIV lipodystrophy more prevalent in women than men in Tamil Nadu, India.
Saramma Mini Jacob (2012)
10.1590/S1677-54492012000200009
Efeito da terapia antirretroviral e dos níveis de carga viral no complexo médio-intimal e no índice tornozelo-braço em pacientes infectados pelo HIV
E. T. Godoi (2012)
Metabolic Complications of Antiretroviral Therapy : Coronary Artery Disease Risks
(2012)
10.2165/11593330-000000000-00000
Antiretroviral Therapy for Children in Resource-Limited Settings
B. Eley (2011)
10.5772/22458
Future Perspectives in NNRTI-Based Therapy: Bases for Understanding Their Toxicity
A. Blas-García (2011)
Dyslipidemia in HIV-infected individuals Authors
E. Sprinz (2011)
10.2174/1874192401105010049
HIV and HAART-Associated Dyslipidemia
E. Feeney (2011)
10.1007/978-0-387-09841-8_38
HIV Infection and Diabetes
M. N. Rao (2010)
10.1016/S1557-0843(10)80008-9
Increased risk for type 2 diabetes mellitus with HIV-1 infection
J. G. Ryan (2010)
10.3851/IMP1509
The Protease Inhibitors Ritonavir and Saquinavir Influence Lipid Metabolism: A Pig Model for the Rapid Evaluation of New Drugs
E. Petersen (2010)
10.1016/S1413-8670(10)70115-X
Dyslipidemia in HIV-infected individuals.
E. Sprinz (2010)
10.2147/JEP.S8129
Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose–insulin homeostasis in animal models
S. Mastan (2010)
Monitorização das concentrações plasmáticas de Efavirenz: critérios de aplicabilidade à prática clínica e efeitos do fármaco a longo termo
S. Pereira (2009)
10.1186/1758-5996-1-15
Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
S. Mastan (2009)
10.1097/PRS.0b013e3181904dd9
Wound Infection Rates in Elective Plastic Surgery for HIV-Positive Patients
M. Reilly (2009)
Strategies to limit the metabolic complications of treatment for HIV infection
M. Vonderen (2009)
10.2165/0044011-200929020-00004
Long-Term Evaluation of Glucose Homeostasis in a Cohort of HAART-Treated HIV-Infected Children
A. Viganò (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar